...
首页> 外文期刊>Melanoma research >Detection of nodal micrometastases using immunohistochemistry and PCR in melanoma of the arm and trunk.
【24h】

Detection of nodal micrometastases using immunohistochemistry and PCR in melanoma of the arm and trunk.

机译:使用免疫组织化学和PCR检测手臂和躯干黑色素瘤中的淋巴结微转移。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Sentinel node (SN) mapping and biopsy seems at present the best way to assess the nodal status in cutaneous melanoma without removing the lymphatic chain. The procedure is minimally invasive, safe and low cost, and allows selection of patients who can benefit from elective node dissection. From March 1997 up to July 1999 we examined 112 SNs excised after lymphatic mapping from 95 patients (48 males and 47 females) with stage I cutaneous melanoma affecting the trunk or limbs. Of these, 88 SNs from 74 patients were submitted to polymerase chain reaction (PCR) in order to detect tyrosinase mRNA. A new antibody (anti-tyrosinase, Clone T311, IgG2a type, Lab Vision Corporation) was used to detect nodal micrometastases. The search for micrometastases was histologically positive in 15 SNs and negative in 97. The 88 SNs examined using molecular biology were positive in 40 cases and negative in 48. In 28 only the PCR was positive. The new antibody used to detect micrometastases was shown to be very useful. Cases positive on both conventional histology and PCR were Clark level II or more and were thicker than 0.6 mm. No difference with regard to site or sex was observed. Lymphoedema and hypersensitivity reactions, nor the inability to work, did not occur. Only patients with histologically proven micrometastases underwent elective node dissection. Cases positive only on molecular biology were submitted to close follow-up.
机译:前哨淋巴结(SN)作图和活检似乎是评估皮肤黑色素瘤淋巴结状态而不去除淋巴链的最佳方法。该过程微创,安全且成本低廉,可以选择可以从选择性淋巴结清扫术中受益的患者。从1997年3月至1999年7月,我们检查了95例I期皮肤黑色素瘤(影响躯干或四肢)的患者(112例SN),其中112例SN是在淋巴定位后切除的。其中,来自74例患者的88个SN接受了聚合酶链反应(PCR),以检测酪氨酸酶mRNA。一种新的抗体(抗酪氨酸酶,克隆T311,IgG2a型,Lab Vision Corporation)用于检测淋巴结微转移。组织学上的微转移搜索在15个SN中为组织学阳性,在97个中为阴性。使用分子生物学检查的88个SN在40例中为阳性,在48例中为阴性。在28例中,仅PCR呈阳性。已证明用于检测微转移的新抗体非常有用。在常规组织学和PCR方面均为阳性的病例为克拉克II级或更高,且厚于0.6毫米。在部位或性别方面未观察到差异。并未发生淋巴水肿和超敏反应,也没有发生无法工作的情况。只有经组织学证实为微转移的患者才进行选择性淋巴结清扫术。仅对分子生物学阳性的病例被提交进行密切随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号